GLP-1 drugs are hailed as breakthroughs for obesity and diabetes but criticized over cost, shortages, side effects, and celebrity-driven demand.
The controversy centers on a new class of highly effective anti-obesity medicines, especially GLP-1 and dual incretin drugs such as semaglutide and tirzepatide, sold under brands including Wegovy, Ozempic, Zepbound, and Mounjaro. Originally developed for diabetes, these drugs showed large average weight-loss effects in clinical trials and, in semaglutide’s case, evidence of reduced cardiovascular events in some patients with obesity or overweight. That shifted the debate from whether obesity should be treated mainly through willpower and lifestyle change toward whether it should be treated as a chronic biological disease requiring long-term pharmacotherapy.
The loudest debate often treats the issue as either liberation from fat stigma or surrender to Big Pharma, but both frames miss the deeper structural shift: these drugs are forcing medicine to decide whether body weight is a private lifestyle matter, a chronic disease, a public-health failure, or a consumer good. The answer determines who pays. If insurers and governments cover the drugs broadly, costs could be enormous; if they do not, access will be rationed by income, producing a visibly medicalized form of class privilege.
GLP-1 drugs are hailed as a medical breakthrough but attacked over cost, shortages, side effects and pressure to medicate weight.
GLP-1 drugs are hailed as obesity breakthroughs but fought over for cost, shortages, side effects, stigma and whether medicine is redefining body norms.
Ozempic-style drugs are hailed as medical breakthroughs and attacked over side effects, shortages, cost, stigma and long-term unknowns.
Drugs like Ozempic and Wegovy are praised as medical breakthroughs while critics warn about cost, shortages, side effects, stigma and lifelong dependency.